Physician profile
Travis Goodale
NPI 1063858272
$16,047.18
in general payments reported to CMS, 2019-2025
62 companies · $4,512 in 2025
The $4,512 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $2,256 · 2021: $704 · 2022: $874 · 2023: $2,578 · 2024: $3,167 · 2025: $4,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $20.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,236.59 |
| Education | $20.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,655.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,470.84 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,251.12 | 2019-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $754.73 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $673.69 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $632.89 | 2019-2025 | Korlym |
| Radius Health, INC. | $618.92 | 2019-2025 | Tymlos |
| Abbvie INC. | $614.53 | 2019-2025 | |
| Insulet Corporation | $579.19 | 2020-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.51 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $542.38 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $533.59 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $418.09 | 2019-2023 | Farxiga |
| Zealand Pharma US, INC. | $416.74 | 2020-2021 | |
| Amarin Pharma, INC. | $369.52 | 2019-2021 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $317.80 | 2021-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $306.90 | 2019-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $287.63 | 2025 | Yorvipath |
| Antares Pharma, INC. | $259.69 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Avvisto Therapeutics, LLC | $251.97 | 2025 | Cycloset |
| Companion Medical, INC. | $219.78 | 2019-2020 | |
| Cequr Corporation | $206.19 | 2022-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $200.60 | 2023-2025 | |
| Abbott Laboratories | $198.42 | 2022-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $191.87 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $163.97 | 2019-2021 | |
| Ibsa Pharma INC. | $155.08 | 2019-2025 | Tirosint, Licart, Flector |
| Xeris Pharmaceuticals, INC. | $147.71 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Neurocrine Biosciences, INC. | $146.15 | 2025 | |
| Embecta Corp. | $143.24 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.81 | 2020-2024 | Cycloset |
| Madrigal Pharmaceuticals | $116.01 | 2024-2025 | Resmetirom, Rezdiffra |
| Janssen Pharmaceuticals, INC | $115.14 | 2019-2020 | |
| Becton, Dickinson and Company | $96.08 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $90.67 | 2019 | |
| Esperion Therapeutics, INC. | $87.00 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $83.52 | 2020-2021 | |
| Tolmar, INC. | $83.44 | 2023-2025 | Jatenzo |
| Horizon Therapeutics Plc | $80.71 | 2021-2023 | Tepezza |
| Acella Pharmaceuticals, LLC | $68.69 | 2024-2025 | NP Thyroid 60 |
| Medtronic Minimed, INC. | $68.50 | 2019-2020 | |
| Valeritas, INC. | $66.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.71 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $57.80 | 2019-2024 | Crysvita |
| Verity Pharmaceuticals INC. | $57.00 | 2024-2025 | Tlando |
| Ascensia Diabetes Care US INC. | $55.06 | 2024-2025 | |
| Kyowa Kirin, INC. | $53.16 | 2024 | Crysvita |
| Sequel Med Tech, LLC | $52.05 | 2025 | Twiist |
| Echosens North America, INC. | $45.54 | 2025 | Fibroscan |
| Shire North American Group INC | $43.98 | 2019 | |
| Lifescan, INC. | $35.72 | 2020 | |
| Averitas Pharma INC. | $29.69 | 2023 | Qutenza |
| Opko Pharmaceuticals, LLC | $26.73 | 2021 | |
| Genentech USA, INC. | $23.57 | 2019 | |
| Recordati_rare_diseases_inc. | $20.25 | 2023 | Signifor Lar, Isturisa |
| Halozyme INC | $17.28 | 2023 | |
| Currax Pharmaceuticals LLC | $16.76 | 2025 | Contrave |
| Mallinckrodt Enterprises LLC | $16.27 | 2019 | |
| Medtronic, INC. | $15.76 | 2023 | Intellis Adaptivestim |
| Acerus Pharmaceuticals Corporation | $14.82 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.52 | 2019 | |
| Amryt Pharma Holdings Ltd | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Goodale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.